High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia
Background: B-Acute lymphoblastic leukemia (B-ALL) represents a hematologic malignancy with poor clinical outcome and low survival rates in adult patients. Remission rates in Hispanic population are almost 30 % lower and Overall Survival (OS) nearly two years inferior than those reported in other et...
- Autores:
-
Cruz Rodriguez, Nataly
Combita, Alba L.
Enciso, Leonardo J.
Quijano, Sandra M.
Pinzon, Paula L.
Lozano, Olga C.
Castillo, Juan S.
Li, Li
Bareño, Jose
Cardozo, Claudia
Solano, Julio
Herrera Jauregui, Maria Victoria
Cudris, Jennifer
Zabaleta, Jovanny
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2016
- Institución:
- Pontificia Universidad Javeriana
- Repositorio:
- Repositorio Universidad Javeriana
- Idioma:
- eng
- OAI Identifier:
- oai:repository.javeriana.edu.co:10554/60253
- Acceso en línea:
- https://jeccr.biomedcentral.com/articles/10.1186/s13046-016-0333-z
http://hdl.handle.net/10554/60253
https://doi.org/10.1186/s13046-016-0333-z
- Palabra clave:
- Acute lymphoblastic leukemia
Gene expression profile
Complete remission
Minimal residual disease
Acute lymphoblastic leukemia
Gene expression profile
Complete remission
Minimal residual disease
- Rights
- License
- Atribución-NoComercial 4.0 Internacional
Summary: | Background: B-Acute lymphoblastic leukemia (B-ALL) represents a hematologic malignancy with poor clinical outcome and low survival rates in adult patients. Remission rates in Hispanic population are almost 30 % lower and Overall Survival (OS) nearly two years inferior than those reported in other ethnic groups. Only 61 % of Colombian adult patients with ALL achieve complete remission (CR), median overall survival is 11.3 months and event-free survival (EFS) is 7.34 months. Identification of prognostic factors is crucial for the application of proper treatment strategies and subsequently for successful outcome. Our goal was to identify a gene expression signature that might correlate with response to therapy and evaluate the utility of these as prognostic tool in hispanic patients. Methods: We included 43 adult patients newly diagnosed with B-ALL. We used microarray analysis in order to identify genes that distinguish poor from good response to treatment using differential gene expression analysis. The expression profile was validated by real-time PCR (RT-PCT). Results: We identified 442 differentially expressed genes between responders and non-responders to induction treatment. Hierarchical analysis according to the expression of a 7-gene signature revealed 2 subsets of patients that differed in their clinical characteristics and outcome. Conclusions: Our study suggests that response to induction treatment and clinical outcome of Hispanic patients can be predicted from the onset of the disease and that gene expression profiles can be used to stratify patient risk adequately and accurately. The present study represents the first that shows the gene expression profiling of B-ALL Colombian adults and its relevance for stratification in the early course of disease. |
---|